OncoMatch/Clinical Trials/NCT06398418
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Is NCT06398418 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies R-5780 for solid tumor, adult.
Treatment: R-5780 — The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Melanoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: checkpoint inhibitor
Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1/L1 therapy per RECIST v1.1 defined as subject who has disease progression after receiving at least two complete cycles of ICI (immune checkpoint inhibitors) therapy or disease progression 6 months from initiation of ICI (immune checkpoint inhibitors) therapy while still on active therapy.
Cannot have received: CAR-T cell therapy
Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy
Cannot have received: allogeneic cellular therapy
Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify